Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial

BACKGROUND: Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Stephen A., Dennis, Andrea, Fiore, Martine M., Kelly, Matt D., Kelly, Catherine J., Paredes, Angelo H., Whitehead, Jennifer M., Neubauer, Stefan, Traber, Peter G., Banerjee, Rajarshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128474/
https://www.ncbi.nlm.nih.gov/pubmed/30192782
http://dx.doi.org/10.1371/journal.pone.0203054

Ejemplares similares

Ejemplares similares